Payment overview · 2025
General Payments
$73.21
4 reported records · 4 companies
Healthcare provider profile · identity verified
James D Walter, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DAVISON, MI · NPI 1912009580
Verified facts
What the public records show
CMS Open Payments records show James D Walter, MD received $73.21 in general payments during 2025 across 4 reported records.
Abbott Laboratories accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.49 | 28.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.97 | 25.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.29 | 25.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.46 | 21.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $73.21 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 414 | 115 |
| Hydrochlorothiazide | Hydrochlorothiazide | 308 | 82 |
| Omeprazole | Omeprazole | 296 | 79 |
| Simvastatin | Simvastatin | 260 | 65 |
| Lisinopril | Lisinopril | 257 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 63 |
| Metformin Hcl | Metformin Hcl | 243 | 71 |
| Alprazolam | Alprazolam | 238 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 58 |
| Meloxicam | Meloxicam | 225 | 78 |
| Eliquis | Apixaban | 223 | 44 |
| Sertraline Hcl | Sertraline Hcl | 223 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 58 |
| Fosinopril Sodium | Fosinopril Sodium | 189 | 49 |
| Tramadol Hcl | Tramadol Hcl | 171 | 45 |
| Losartan Potassium | Losartan Potassium | 168 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 41 |
| Allopurinol | Allopurinol | 114 | 31 |
| Ibuprofen | Ibuprofen | 114 | 40 |
| Potassium Chloride | Potassium Chloride | 112 | 33 |
| Furosemide | Furosemide | 102 | 30 |
| Januvia | Sitagliptin Phosphate | 102 | 22 |
| Atenolol | Atenolol | 94 | 24 |
| Gabapentin | Gabapentin | 88 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 32 |
| Trazodone Hcl | Trazodone Hcl | 85 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 21 |
| Ozempic | Semaglutide | 78 | 13 |
| Glimepiride | Glimepiride | 71 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 18 |
| Finasteride | Finasteride | 67 | 18 |
| Prednisone | Prednisone | 67 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 19 |
| Lorazepam | Lorazepam | 66 | 21 |
| Colchicine | Colchicine | 65 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 18 |
| Enalapril Maleate | Enalapril Maleate | 61 | 14 |
| Glipizide | Glipizide | 60 | 17 |
| Celecoxib | Celecoxib | 59 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 25 |
| Famotidine | Famotidine | 51 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Hydrocortisone | Hydrocortisone | 47 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 36 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Carvedilol | Carvedilol | 42 | 11 |
| Minocycline Hcl | Minocycline Hcl | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 12 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 40 | suppressed |
| Rybelsus | Semaglutide | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 14 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Testosterone | Testosterone | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Glyburide | Glyburide | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 15 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 13 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Digoxin | Digoxin | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73.21 · 4 records | Abbott Laboratories | AREXVY, FREESTYLE LIBRE 3, QULIPTA, UBRELVY, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error